The decision-making forum for new methods (Beslutningsforum for nye metoder) says yes to new drug for the treatment of atopic eczema, also known as childhood eczema.
The new drug Dupilumab should be used by adults and children over the age of 12 who have not achieved adequate results when using other medicines. The drug will be available from April 1st this year.
Leader Stig A. Slørdahl of the decision-making forum states that the price of the drug has been decisive.
“Better and new documentation on the effect, in addition to the fact that the supplier has offered a new price, allows the Decision Forum to introduce the drug,” he says in a press release.
Atopic eczema produces dry, itchy and inflamed skin. The disease affects young children in particular, and is therefore called child eczema.
© NTB Scanpix / #Norway Today